Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

All-trans retinoic acid and RARβ agonists enhance the efficacy of IMiD-based treatments for t(4;14) multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MXMiao XianQYQing Yi

Discussion

Loading...

Member takes

Overview

Combination therapies enhance treatment efficacy in t(4;14) multiple myeloma, suggesting new therapeutic strategies for IMiD resistance.

Key Points

  • The aim is to improve the efficacy of IMiD treatments in patients with t(4;14) multiple myeloma.
  • High-throughput screening of FDA-approved drugs was conducted to identify candidates enhancing sensitivity to chemotherapy.
  • In vitro experiments tested the effects of all-trans retinoic acid and RARβ agonists on MM cells.
  • CRISPR/Cas9 was utilized to generate RARβ knockout MM cell lines to assess the role of RARβ in treatment response.
  • All-trans retinoic acid enhanced the sensitivity of t(4;14) multiple myeloma cells to IMiDs.
  • RARβ agonists demonstrated significant efficacy in combination with IMiD treatments.
  • Mechanistic studies revealed downregulation of FGFR3 and suppression of the PI3K/AKT signaling pathway.

Cite This Study

Xian et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d133https://doi.org/10.1182/blood-2025-5817
View Full Paper
Ask AI
Bookmark
Share